A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.

MLA

Furman, Wayne L., et al. “A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 25, no. 21, Nov. 2019, pp. 6320–28. EBSCOhost, https://doi.org/10.1158/1078-0432.CCR-19-1452.

APA

Furman, W. L., Federico, S. M., McCarville, M. B., Shulkin, B. L., Davidoff, A. M., Krasin, M. J., Sahr, N., Sykes, A., Wu, J., Brennan, R. C., Bishop, M. W., Helmig, S., Stewart, E., Navid, F., Triplett, B., Santana, V. M., Bahrami, A., Anthony, G., Yu, A. L., … Pappo, A. S. (2019). A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 25(21), 6320–6328. https://doi.org/10.1158/1078-0432.CCR-19-1452

Chicago

Furman, Wayne L, Sara M Federico, Mary Beth McCarville, Barry L Shulkin, Andrew M Davidoff, Matthew J Krasin, Natasha Sahr, et al. 2019. “A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 25 (21): 6320–28. doi:10.1158/1078-0432.CCR-19-1452.